Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: meropenem-vaborbactam

  • Meropenem-vaborbactam

    Meropenem-vaborbactam (Vabomere) is the latest β-lactam/β-lactamase inhibitor (BLI), approved by the FDA in August 2017 for treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in adults older than 18 years of age.